139 related articles for article (PubMed ID: 22836058)
21. Analysis of the prognostic impact of tumor embolization before definitive radiotherapy for cervical carcinoma.
Kapp KS; Poschauko J; Tauss J; Berghold A; Oechs A; Lahousen M; Petru E; Winter R; Kapp DS
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1399-404. PubMed ID: 16029799
[TBL] [Abstract][Full Text] [Related]
22. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
23. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
Eur J Cancer; 2008 Jan; 44(1):54-60. PubMed ID: 17976974
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
25. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
Lee HW; Hwang YH; Han JH; Choi JH; Kang SY; Jeong SH; Ann MS; Oh YT; Kim JH; Kim CH; Sheen SS
Oral Oncol; 2010 Mar; 46(3):209-13. PubMed ID: 20153243
[TBL] [Abstract][Full Text] [Related]
26. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
[TBL] [Abstract][Full Text] [Related]
27. Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study.
Hequet D; Marchand E; Place V; Fourchotte V; De La Rochefordière A; Dridi S; Coutant C; Lecuru F; Bats AS; Koskas M; Bretel JJ; Bricou A; Delpech Y; Barranger E
Eur J Surg Oncol; 2013 Dec; 39(12):1428-34. PubMed ID: 24183796
[TBL] [Abstract][Full Text] [Related]
28. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy.
Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Sotoca A; Pérez-Ruiz E; Lanzós E
Am J Clin Oncol; 2011 Aug; 34(4):395-400. PubMed ID: 20859196
[TBL] [Abstract][Full Text] [Related]
29. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
Gielda BT; Mehta P; Khan A; Marsh JC; Zusag TW; Warren WH; Fidler MJ; Abrams RA; Bonomi P; Liptay M; Faber LP
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):985-91. PubMed ID: 20932684
[TBL] [Abstract][Full Text] [Related]
30. The value of prognostic factors for uterine cervical cancer patients treated with irradiation alone.
Grigiene R; Valuckas KP; Aleknavicius E; Kurtinaitis J; Letautiene SR
BMC Cancer; 2007 Dec; 7():234. PubMed ID: 18154683
[TBL] [Abstract][Full Text] [Related]
31. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
Chan SH; Cheung FM; Ng WT; Choi CW; Cheung KN; Yiu KH; Lee AW
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1414-20. PubMed ID: 20605357
[TBL] [Abstract][Full Text] [Related]
32. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.
Kang SY; Han JH; Lee KJ; Choi JH; Park JI; Kim HI; Lee HW; Jang JH; Park JS; Kim HC; Kang S; Oh YT; Chun M; Kim JH; Sheen SS; Lim HY
Clin Cancer Res; 2007 Jul; 13(14):4146-53. PubMed ID: 17634542
[TBL] [Abstract][Full Text] [Related]
33. Survivin protein as predictor of pathologic response in patients with locally advanced cervical cancer treated with chemoradiation followed by radical surgery.
Zannoni GF; Petrillo M; Vellone VG; Martinelli E; Chiarello G; Ferrandina G; Scambia G
Hum Pathol; 2014 Sep; 45(9):1872-8. PubMed ID: 24997647
[TBL] [Abstract][Full Text] [Related]
34. Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach.
Gadducci A; Fabrini MG; Perrone F; Manfredi B; Fanucchi A; Laliscia C; Barsotti C; Scotti V; Genazzani AR; Greco C
Anticancer Res; 2010 Sep; 30(9):3731-5. PubMed ID: 20944162
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic factors for central recurrence in patients with locally advanced bulky cervical cancer.
Lee WM; Park SI; Kim BJ; Kim MH; Choi SC; Lee ED; Ryu SY
Eur J Obstet Gynecol Reprod Biol; 2012 Apr; 161(2):219-23. PubMed ID: 22326616
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report.
Fuso L; Mazzola S; Marocco F; Ferrero A; Dompè D; Carus AP; Zola P
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S187-91. PubMed ID: 16185756
[TBL] [Abstract][Full Text] [Related]
37. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
[TBL] [Abstract][Full Text] [Related]
38. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
39. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
Darcy KM; Tian C; Reed E
Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
[TBL] [Abstract][Full Text] [Related]
40. Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma.
Goksedef BP; Kunos C; Belinson JL; Rose PG
Am J Obstet Gynecol; 2009 Feb; 200(2):175.e1-5. PubMed ID: 19091305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
